3 ASX Penny Stocks With Market Caps Under A$3B

As the ASX 200 experiences a slight decline, contrasting with Wall Street's tech-driven surge, Australian investors are keeping a keen eye on market movements and company updates. Amidst these shifts, penny stocks continue to intrigue investors with their potential for growth and value. While the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique opportunities when supported by robust financials.

Top 10 Penny Stocks In Australia

Name	Share Price	Market Cap	Financial Health Rating
Embark Early Education (ASX:EVO)	A$0.77	A$141.28M	★★★★☆☆
LaserBond (ASX:LBL)	A$0.585	A$68.57M	★★★★★★
SHAPE Australia (ASX:SHA)	A$2.94	A$243.76M	★★★★★★
Austin Engineering (ASX:ANG)	A$0.525	A$325.58M	★★★★★☆
Helloworld Travel (ASX:HLO)	A$1.98	A$322.38M	★★★★★★
MaxiPARTS (ASX:MXI)	A$1.94	A$107.31M	★★★★★★
GTN (ASX:GTN)	A$0.555	A$108.99M	★★★★★★
IVE Group (ASX:IGL)	A$2.15	A$333.01M	★★★★☆☆
Servcorp (ASX:SRV)	A$4.95	A$488.43M	★★★★☆☆
SKS Technologies Group (ASX:SKS)	A$1.59	A$247.67M	★★★★★★

Click here to see the full list of 1,026 stocks from our ASX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Aroa Biosurgery (ASX:ARX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$260.40 million.

Operations: The company's revenue is primarily derived from its operations in developing, manufacturing, and selling soft tissue repair products, totaling NZ$76.35 million.

Market Cap: A$260.4M

Aroa Biosurgery is navigating the penny stock landscape with a market cap of A$260.40 million and revenue of NZ$76.35 million, primarily from its soft tissue repair products. Despite being unprofitable, it has shown a reduction in net losses over five years at 20.8% annually, and recent half-year results revealed sales growth to NZ$39.16 million while narrowing net losses to NZ$3.29 million from the previous year’s NZ$6.31 million loss. The company is debt-free with short-term assets exceeding liabilities, indicating financial stability amidst volatility in earnings growth forecasts at 59.67% per year according to analysts' consensus estimates.

• Click to explore a detailed breakdown of our findings in Aroa Biosurgery's financial health report.
• Understand Aroa Biosurgery's earnings outlook by examining our growth report.

MFF Capital Investments (ASX:MFF)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: MFF Capital Investments Limited is an investment firm manager with a market capitalization of A$2.78 billion.

Operations: The company generates revenue primarily from its equity investment segment, which amounts to A$659.96 million.

Market Cap: A$2.78B

MFF Capital Investments, with a market cap of A$2.78 billion, stands out in the penny stock arena due to its robust financial health and performance metrics. The company boasts high-quality earnings with an impressive net profit margin of 67.8% and a strong return on equity at 21.6%. Its debt is well-managed, covered by operating cash flow at 206.2%, and it holds more cash than total debt, ensuring financial stability. MFF's earnings have grown significantly by 38.3% over the past year, surpassing industry averages, while trading below its estimated fair value enhances its appeal as a potential investment opportunity amidst recent management changes.

• Jump into the full analysis health report here for a deeper understanding of MFF Capital Investments.
• Understand MFF Capital Investments' track record by examining our performance history report.

Ridley (ASX:RIC)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ridley Corporation Limited, with a market cap of A$872.17 million, operates in Australia providing animal nutrition solutions through its subsidiaries.

Operations: The company generates revenue from two main segments: Bulk Stockfeeds, contributing A$886.59 million, and Packaged/Ingredients, which accounts for A$376.31 million.

Market Cap: A$872.17M

Ridley Corporation Limited, with a market cap of A$872.17 million, presents a mixed picture in the penny stock landscape. The company demonstrates financial stability with short-term assets exceeding both its long-term and short-term liabilities, and interest payments well-covered by EBIT. However, recent negative earnings growth contrasts with significant profit growth over the past five years. Ridley's net debt to equity ratio is satisfactory at 35.8%, though its return on equity remains low at 12.3%. Despite trading below estimated fair value, Ridley faces challenges like an unstable dividend track record and declining profit margins compared to last year.

• Get an in-depth perspective on Ridley's performance by reading our balance sheet health report here.
• Evaluate Ridley's prospects by accessing our earnings growth report.

Next Steps

• Dive into all 1,026 of the ASX Penny Stocks we have identified here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com